F10 and transient ischemic attack: AF, atrial fibrillation; CAD, coronary artery disease; CrCl, creatinine clearance; DOACS, direct oral anticoagulants; DTI, direct thrombin inhibitors; FXaI, factor Xa inhibitors; HR, hazard ratio; ICH, intracranial hemorrhage; INR, international normalized ratio; NOACs, non-vitamin K antagonists; NVAF, non-valvular atrial fibrillation; ROCKET AF trial, Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; TIA, transient ischemic attack; VKAs, vitamin K antagonists